It can both "anti -tumor" and "protect the bone marrow". The potential of CDK4/6 inhibitors is unlimited!
*For medical professionals for reading reference*This article is only used to prov...
Lessons from PI3K inhibitors: High ORR data may be just "short checks"
Lessons from PI3K inhibitors: High ORR data may be just short checksSource: amino ...
The target of the non -patent medicine "breaking the situation" or the "lost person": Do not superstitize FIC
The target of the non -patent medicine breaking the situation or the lost person: Do not superstitize FICSource: amino observation/Cai JiuFor innovative medicines, the highest hall is undoubtedly
"Self -knife" 2.5 billion U.S. dollars, Bilemei Shi Guibao Gambling Revelation
Source: amino observation/Fang TaozhiThe troubles between pharmaceutical companies...
PD-L1 inhibitors Ervli Mipida "sharp blade out of the sheath", showing the "hard power" of colorectal cancer immunotherapy
*For medical professionals for reading reference*This article is only used to prov...
Nuggets Innovation Pharmaceuticals ｜ Can the new crown oral medication that is not good for progress allows Ge Gift Pharmaceuticals to "counterattack"?Corning Jerry declared domestic first dual anti -ADC clinical clinical
Nuggets Innovation Pharmaceuticals was jointly launched by the Daily Economic News...
New targets, new hope -these drugs at the 20122 WCLC conference are "hot"!
*For medical professionals for reading referenceQuickly punch the latest research ...
2022 WCLC 丨 NSCLC KRAS Huazhang sounds, four studies and one article speed view
*For medical professionals for reading referenceWhat are the wonderful studies of ...
Belle Schimibao will soon complete the acquisition of $ 4.1 billion!
Source: Yaozhi.com/ForestOn August 16, BMS announced that it had received a merger license from Federal Cartel Office in Germany and was expected to complete the transaction tomorrow. Earlier this sum
What is the potential of Nuo Chengjian from Biotech to Biopharma?
What is the potential of Nuo Chengjian from Biotech to Biopharma?Source: Yaizhi.co...
Who can surpass the "Lipur" 20 years ago?New targets to reduce lipids
Is there any room for innovation?On October 9, 2002, FDA officially confirmed that...
[Transfer] G12C mutation is difficult to create "medicine king", KRAS target needs to break through the adaptive ceiling
[Transfer] G12C mutation is difficult to create medicine king, KRAS target needs t...
The results of the world's first PD-1 inhibitors head-up research results were announced: Civili Single Single Anti-Domestic Immunohic Drug Ling Cancer First Line Treatment "Strongest Voice"
*For medical professionals for reading referenceCTONG1901 [1] Study, the world's f...
Anti -cancer new drug research and development agent Tajiri Biocence of several hundred million yuan B financing
On July 5th, Capital State learned that according to IT orange, Tagiri Bio recently announced the completion of hundreds of millions of yuan B financing, and the investor has not disclosed it yet.The
Junshi Biological: JS105 Clinical Test Application to get FDA approval
On July 4, Capital State learned that Junshi (01877.HK/688180.SH) disclosed a announcement on the FDA approval of the JS105 clinical trial application.According to the announcement, the company and pa
Why is the molecular detection of non -small cell lung cancer so important?This article tells you ...
*For medical professionals for reading referenceOne text is clear, come to collect...
Hengrui Pharmaceutical's new AR inhibitor is approved by patients with prostate cancer to usher in a new choice
Zhongxin Jingwei, July 2nd. On June 29th, Hengrui Pharmaceutical Announcement anno...
21 Talks ｜ Ou Silang, Global Vice President of Albervis and General Manager of China: Digging high -quality tracks, staying away from the "Red Sea"
The 21st Century Business Herald reporter Ji Yuanyuan intern Guo Zhirui reported that in recent years, JAK inhibitors have become a popular track for domestic and foreign pharmaceutical companies. As
Quickly effective and lasting benefits, Savidi helps the primary meta to expand metastatic lung cancer patients quickly reverse the trend
*For medical professionals for reading referenceMET amplification patients cannot ...